Advertisement

Andere Tumoren

Chapter
  • 1.5k Downloads

Zusammenfassung

Das kutame Plattenepithelkarzinom ist ein bösartiger Hauttumor ausgehend von den Keratinozyten des Stratum spinosum (Synonym Spinaliom, squamous cell carcinoma, SCC), der meist auf dem Boden einer Präkanzerose entsteht, lokal invasiv wächst und bei etwa 5% der Patienten metastasiert.

Literatur

  1. Agelli M, Clegg LX (2003) Epidemiology of primary Merkel cell carcinoma in the United StatesJ Am Acad Dermatol 49(5):832–41CrossRefGoogle Scholar
  2. Agelli M, Clegg LX, Becker JC, Rollison DE (2010) The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer 34(1):14–37PubMedCrossRefGoogle Scholar
  3. Agulnik M, Okuno SH, Von Mehren M, Jovanovic B, Brockstein B, Benjamin RS, Evens AM (2009) An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. Proc Am Soc Clin Oncol 27:abstr 10522Google Scholar
  4. Alter M, Kapp A, Gutzmer R (2011) Successful treatment of an angiosarcoma of the head - options for systemic therapy. J Dtsch Dermatol Ges 9(6):477–8PubMedGoogle Scholar
  5. Arnaoutoglou C, Lykissas MG, Gelalis ID, Batistatou A, Goussia A, Doukas M, Xenakis TA (2010) Low grade fibromyxoid sarcoma: a case report and review of the literature. J Orthop Surg Res 5:49PubMedCrossRefGoogle Scholar
  6. Baselga J, Trigo JM, Bourhis J, Tortochaux J, CortERLINK "ht, Hitt R, GascERLI, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–77PubMedCrossRefGoogle Scholar
  7. Becker JC. (2010) Merkel cell carcinoma. Ann Oncol 21 Suppl 7:vii81–5Google Scholar
  8. Bendix-Hansen K, Myhre-Jensen O, Kaae S (1983) Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg 17(3):247–52PubMedCrossRefGoogle Scholar
  9. Berger DP, Engelhardt R, Mertelsmann R Das Rote Buch-Hämatologie und Internistische Onkologie. 4. Auflage. ecomed Medizin, Landsberg 2010Google Scholar
  10. Bolognia JL, Jorizzo JL, Schaffer JV (2012) Dermatology, 3rd ed. Elsevier SaundersGoogle Scholar
  11. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA; International Society for Photodynamic Therapy in Dermatology (2007) Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. Am Acad Dermatol 56(1):125–43CrossRefGoogle Scholar
  12. Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP (1997) Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer 79(5):915–9PubMedCrossRefGoogle Scholar
  13. Bruce T Burns, Sybelle A Blakey, Wayne B Harris (2002) Complete response of metastatic angiosarcoma to liposomal doxorubicin and interferon-α2a. Proc Am Soc Clin Oncol 21:abs 2939Google Scholar
  14. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(34):8646–54PubMedCrossRefGoogle Scholar
  15. Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, Tabaro G, Mazzoleni F (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23(2):181–4PubMedCrossRefGoogle Scholar
  16. Chuang TY, Su WP, Muller SA (1990) Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol 23(2 Pt 1):254–6PubMedCrossRefGoogle Scholar
  17. Chung EB, Enzinger FM (1983) Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Ann J Surg Pathol 7: 405–413CrossRefGoogle Scholar
  18. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE (2005) Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11(23):8418–24PubMedCrossRefGoogle Scholar
  19. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21(10):1980–7PubMedCrossRefGoogle Scholar
  20. Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M, Vogt T (2004) Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch Dermatol 140(12):1504–7PubMedCrossRefGoogle Scholar
  21. Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB (1999) Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer 86(6):969–75PubMedCrossRefGoogle Scholar
  22. Dummer R, Panizzon R, Burg G (1998) Physikalische Therapie in der Dermatoonkologie. BlackwellGoogle Scholar
  23. Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10):2034–7PubMedCrossRefGoogle Scholar
  24. Fields JP, Helwig EB (1981) Leiomyosarcoma of the skin and subcutaneous tissue. Cancer 47(1):156–69PubMedCrossRefGoogle Scholar
  25. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al. (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10(8):1245–51PubMedGoogle Scholar
  26. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG (2005) A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11(3):241–7PubMedCrossRefGoogle Scholar
  27. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O’Mara MM, D’Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27(19):3154–60PubMedCrossRefGoogle Scholar
  28. Goessling W, McKee PH, Mayer RJ (2002) Merkel cell carcinoma. J Clin Oncol 20(2):588–98PubMedCrossRefGoogle Scholar
  29. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–35PubMedCrossRefGoogle Scholar
  30. Haas RL, Keus RB, Loftus BM, Rutgers EJ, van Coevorden F, Bartelink H (1997) The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer 33(7):1055–60PubMedCrossRefGoogle Scholar
  31. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Onco 23(24):5578–87CrossRefGoogle Scholar
  32. Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R (2000) Classic kaposi sarcoma: epidemiology and risk factors. Cancer 88(3):500–17PubMedCrossRefGoogle Scholar
  33. Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, Longy M, Maki RG, Coindre JM, Antonescu CR (2012) Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 118(23):5878–87PubMedCrossRefGoogle Scholar
  34. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883–9PubMedCrossRefGoogle Scholar
  35. Khansur T, Kennedy A (1991) Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67(8):2030–2PubMedCrossRefGoogle Scholar
  36. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ (2005) Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J Clin Oncol 23(5):982–9PubMedCrossRefGoogle Scholar
  37. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–95PubMedCrossRefGoogle Scholar
  38. Lemm Doreen, Mügge LO, Mentzel T, Höffken K (2009) Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 135: 653–665PubMedCrossRefGoogle Scholar
  39. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18(5):1435–46PubMedCrossRefGoogle Scholar
  40. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–41PubMedCrossRefGoogle Scholar
  41. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study (2007) Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25(21):3144–50Google Scholar
  42. Lucas DR, Nascimento A, Sim FH (1992) Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol 16: 1197–1204PubMedCrossRefGoogle Scholar
  43. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sørensen P, Nielsen T, Lisby S, Clement PM (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12(4):333–43PubMedCrossRefGoogle Scholar
  44. Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, BlachRLINK, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27(19):3133–40PubMedCrossRefGoogle Scholar
  45. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, MentrRLI, Avril MF (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29(25):3419–26PubMedCrossRefGoogle Scholar
  46. Monnier D, Vidal C, Martin L, Danzon A, Pelletier F, Puzenat E, Algros MP, Blanc D, Laurent R, Humbert PH, Aubin F (2006) Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol 20(10):1237–42PubMedCrossRefGoogle Scholar
  47. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C (2007) Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 110(3):648–51PubMedCrossRefGoogle Scholar
  48. Ohguri T, Imada H, Nomoto S, Yahara K, Hisaoka M, Hashimoto H, Tokura Y, Nakamura K, Shioyama Y, Honda H, Terashima H, Moroi Y, Furue M, Korogi Y (2005) Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys 61(5):1446–53PubMedCrossRefGoogle Scholar
  49. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY (2008) Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 26(32):5269–74PubMedCrossRefGoogle Scholar
  50. Pitman SW, Miller D, Weichselbaum R (1978) Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope 88(4):632–8PubMedGoogle Scholar
  51. Reichgelt BA, Visser O (2011) Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. Eur J Cancer 47(4):579–85PubMedCrossRefGoogle Scholar
  52. Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, Guillaume JC, Armand JP, Avril MF (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66(8):1692–6PubMedCrossRefGoogle Scholar
  53. Schlag PM, Hartmann JT, Budach V (2011) Weichgewebetumoren. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  54. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY (2008) Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44(16):2433–6PubMedCrossRefGoogle Scholar
  55. Serraino D, Angeletti C, Carrieri MP, Longo B, Piche M, Piselli P, Arbustini E, Burra P, Citterio F, Colombo V, Fuzibet JG, Dal Bello B, Targhetta S, Grasso M, Pozzetto U, Bellelli S, Dorrucci M, Dal Maso L, Busnach G, Pradier C, Rezza G; for the Immunesuppression and Cancer Study Group (2005) Kaposi’s sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation 80(12):1699–704PubMedCrossRefGoogle Scholar
  56. Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM (2002) Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20(2):364–70PubMedCrossRefGoogle Scholar
  57. Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104(2):361–6PubMedCrossRefGoogle Scholar
  58. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG (2012) Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 23(2):501–8PubMedCrossRefGoogle Scholar
  59. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27(11):1864–71PubMedCrossRefGoogle Scholar
  60. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S (2007) The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 12(11):1351–60PubMedCrossRefGoogle Scholar
  61. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 119(12):2922–30PubMedCrossRefGoogle Scholar
  62. Uldrick TS, Whitby D (2011) Update on kshv epidemiology, kaposi sarcoma pathogenesis and treatment of kaposi sarcoma. Cancer Letters 305: 150–162PubMedCrossRefGoogle Scholar
  63. Vermorken JB Stöhlmacher J, Davidenko I (2010) lba26 primary efficacy and safety results of spectrum, a phase 3 trial in patients (pts) with recurrent and/or metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB). Ann Oncol 21 (suppl 8):viii12Google Scholar
  64. Vermorken JB, Guigay J, Mesia R, Trigo JM, Keilholz U, Kerber A, Bethe U, Picard M, Brummendorf TH (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104(11):1691–6PubMedCrossRefGoogle Scholar
  65. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J (2008) Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112(12):2710–9PubMedCrossRefGoogle Scholar
  66. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–27PubMedCrossRefGoogle Scholar
  67. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16):2171–7PubMedCrossRefGoogle Scholar
  68. Verschraegen CF, Quinn R, Rabinowitz I, Arias-Pulido H, CMuller C (2008) Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). Proc Am Soc Clin Oncol 26:abstr 10534Google Scholar
  69. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98(10):2251–6PubMedCrossRefGoogle Scholar
  70. von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118(3):770–6CrossRefGoogle Scholar
  71. Weichselbaum RR, Miller D, Pitman SW, Kirkwood J (1978) Initial adjuvant weekly high dose methotrexate with leucovorin rescue in advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 4(7–8):671–4PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Universitätsklinikum ErlangenHautklinikErlangenDeutschland
  2. 2.Privatpraxis für Dermatologie und Ästhetische MedizinRzany und HundBerlinDeutschland

Personalised recommendations